We found that 28.9% of the 495 colorectal cancer precursor lesions had mutations in the KRAS gene which was in range with the 15.0%-75.0% prevalence of KRAS mutations in polyps reported in previous studies [39-51]. This evidence concerns the gene KRAS and colorectal cancer.